Gene: E2F3

1871
E2F-3
E2F transcription factor 3
protein-coding
6p22.3
Ensembl:ENSG00000112242 MIM:600427 Vega:OTTHUMG00000016389 UniprotKB:O00716
NG_029591.1
PubMed
0   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
4.888e-1 (AD)  1.826e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
PRKCI0.909
RUNDC10.899
TMX30.896
UBE3C0.893
CDK200.888
SLC35B40.887
DHX330.886
FZD30.884
COG10.884
CELF20.884

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.475
CTNNA3-0.449
HEY2-0.448
TGFB3-0.425
MYL3-0.422
CSAG1-0.418
OR4F29-0.411
MTRNR2L6-0.411
ANXA13-0.41
RAI14-0.404

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C5321622-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased expression of E2F3 mRNA"20453058
C5112952,2',4,4'-tetrabromodiphenyl ether"2,2',4,4'-tetrabromodiphenyl ether results in decreased expression of E2F3 mRNA"26988655
C5805985-OH-BDE-475-OH-BDE-47 results in increased expression of E2F3 mRNA26988655
C5805996-OH-BDE-476-OH-BDE-47 results in increased expression of E2F3 mRNA26988655
D000082AcetaminophenAcetaminophen results in decreased expression of E2F3 mRNA26690555
D018501Antirheumatic AgentsAntirheumatic Agents results in decreased expression of E2F3 mRNA24449571
D001151ArsenicArsenic results in increased expression of E2F3 mRNA11134558
C006632arsenic trioxidearsenic trioxide results in increased expression of E2F3 mRNA20862710
C006632arsenic trioxideE2F3 protein results in increased susceptibility to arsenic trioxide20707922
C547126AZM551248AZM551248 results in decreased expression of E2F3 mRNA22323515
C006703benzo(b)fluoranthenebenzo(b)fluoranthene results in increased expression of E2F3 mRNA26377693
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of E2F3 mRNA"19150397
D004958Estradiol[Estradiol co-treated with EGF protein] results in increased expression of E2F3 mRNA24758408
D004958EstradiolEstradiol results in increased expression of E2F3 mRNA20106945
D004958EstradiolESR1 protein promotes the reaction [Estradiol results in increased expression of E2F3 mRNA]25210133
D004958EstradiolEstradiol results in increased expression of E2F3 mRNA25210133
C006780bisphenol Abisphenol A results in increased expression of E2F3 mRNA29027980
C006780bisphenol Abisphenol A results in increased expression of E2F3 protein21277958
C006780bisphenol Abisphenol A affects the methylation of E2F3 promoter27334623
C006780bisphenol Abisphenol A results in decreased expression of E2F3 mRNA25181051
D019256Cadmium ChlorideCadmium Chloride results in decreased methylation of E2F3 promoter22457795
D003520CyclophosphamideE2F3 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]16896004
D016572CyclosporineCyclosporine results in increased expression of E2F3 mRNA20106945|2556210
C014347decitabinedecitabine results in increased expression of E2F3 mRNA27915011
D003993Dibutyl PhthalateDibutyl Phthalate results in decreased expression of E2F3 mRNA21266533
D002945CisplatinCisplatin results in decreased expression of E2F3 mRNA21603599
D004051Diethylhexyl PhthalateDiethylhexyl Phthalate results in increased expression of E2F3 mRNA19850644
D004051Diethylhexyl PhthalatePPARA protein promotes the reaction [Diethylhexyl Phthalate results in increased expression of E2F3 mRNA]19850644
D004317DoxorubicinE2F3 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]16896004
D052244Endocrine DisruptorsEndocrine Disruptors results in decreased expression of E2F3 mRNA25198161
D005054EugenolEugenol results in decreased expression of E2F3 mRNA15574415
D005054EugenolEugenol results in decreased expression of E2F3 protein15574415
D0150732-Acetylaminofluorene2-Acetylaminofluorene results in decreased expression of E2F3 protein15158336|1916741
D005472FluorouracilE2F3 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]16896004
D005557FormaldehydeFormaldehyde results in decreased expression of E2F3 mRNA20655997
D005557FormaldehydeFormaldehyde results in increased expression of E2F3 mRNA23649840
C039281furanfuran results in increased expression of E2F3 mRNA20562052
C001277geldanamycingeldanamycin results in increased expression of E2F3 mRNA26705709
D007213IndomethacinIndomethacin results in decreased expression of E2F3 mRNA16984733
C561695(+)-JQ1 compound(+)-JQ1 compound affects the expression of E2F3 protein27440272
C011890kojic acidkojic acid results in increased expression of E2F3 mRNA16595896
C038753leptomycin Bleptomycin B results in increased expression of E2F3 mRNA20803015
D008012LidocaineLidocaine affects the expression of E2F3 mRNA18931217
D008070LipopolysaccharidesLipopolysaccharides results in increased expression of E2F3 mRNA12057914
D008727MethotrexateMethotrexate results in decreased expression of E2F3 mRNA24449571
C437683motexafin gadoliniummotexafin gadolinium results in increased expression of E2F3 mRNA16357179
C437683motexafin gadolinium[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of E2F3 mRNA16357179
D037742Nanotubes, Carbon"Nanotubes, Carbon results in increased expression of E2F3 mRNA"25554681
D009532NickelNickel results in increased expression of E2F3 mRNA24768652
C028007nickel monoxidenickel monoxide results in increased expression of E2F3 mRNA19167457
D009538NicotineNicotine promotes the reaction [E2F3 protein binds to CDC25A promoter]16862215
D009538NicotineNicotine promotes the reaction [E2F3 protein binds to CDC6 promoter]16862215
D0151124-Nitroquinoline-1-oxide4-Nitroquinoline-1-oxide results in increased expression of E2F3 mRNA22561872
C572573N-nitroso-tris-chloroethylureaN-nitroso-tris-chloroethylurea results in increased expression of E2F3 mRNA27935865
D010100OxygenOxygen deficiency results in increased expression of E2F3 mRNA17914565
D017239PaclitaxelE2F3 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]16896004
D010575PesticidesPesticides results in decreased methylation of E2F3 gene28396702
D010634PhenobarbitalNR1I3 protein affects the reaction [Phenobarbital results in increased expression of E2F3 mRNA]19482888
D010634PhenobarbitalPhenobarbital results in increased expression of E2F3 mRNA19482888
D010656PhenylephrinePhenylephrine results in increased expression of E2F3 protein12682052
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in decreased expression of E2F3 mRNA26272509
C006253pirinixic acidpirinixic acid results in increased expression of E2F3 mRNA18301758
C060540polyhexamethyleneguanidinepolyhexamethyleneguanidine results in increased expression of E2F3 mRNA24583197
D011794QuercetinQuercetin results in decreased expression of E2F3 mRNA14715546
D017382Reactive Oxygen SpeciesReactive Oxygen Species results in decreased expression of E2F3 mRNA25800948
C059514resveratrolresveratrol results in decreased expression of E2F3 protein23954321
C009166retinol acetateretinol acetate results in increased expression of E2F3 mRNA16772331
D019438RitonavirRitonavir results in decreased expression of E2F3 mRNA19386116
C410733scriptaidscriptaid affects the expression of E2F3 mRNA18813790
D012835Silver NitrateSilver Nitrate analog results in increased expression of E2F3 mRNA22831968
C017947sodium arsenitesodium arsenite results in increased expression of E2F3 mRNA12760830
D018038Sodium SeleniteSodium Selenite results in decreased expression of E2F3 mRNA18175754
D013629TamoxifenTamoxifen results in decreased expression of E2F3 mRNA25123088
C004648testosterone enanthatetestosterone enanthate affects the expression of E2F3 mRNA17440010
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of E2F3 mRNA21570461
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of E2F3 mRNA24058054
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of E2F3 mRNA15667827
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of E2F3 mRNA22298810
D013853ThioacetamideThioacetamide results in increased expression of E2F3 mRNA22659510
C012589trichostatin Atrichostatin A affects the expression of E2F3 mRNA28542535
C015559trimellitic anhydridetrimellitic anhydride results in increased expression of E2F3 mRNA19042947
C001899triptolidetriptolide results in increased expression of E2F3 mRNA23639586
C000602704UF010 compoundUF010 compound results in decreased activity of E2F3 protein25699604
D014635Valproic AcidValproic Acid affects the expression of E2F3 mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of E2F3 mRNA23179753
D024483Vitamin K 3Vitamin K 3 affects the expression of E2F3 mRNA20044591
D014874Water Pollutants, Chemical"Water Pollutants, Chemical results in decreased expression of E2F3 mRNA"25198161
D019345Zinc Acetate[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of E2F3 mRNA16357179
D019345Zinc AcetateZinc Acetate results in increased expression of E2F3 mRNA16357179

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0000977RNA polymerase II regulatory region sequence-specific DNA bindingcontributes_toIDA7739537  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-ISA-  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-ISM19274049  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-NAS19274049  
GO:0000987proximal promoter sequence-specific DNA binding-IDA15735762  
GO:0001228transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding-IC-  
GO:0001228transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA bindingcontributes_toIDA7739537  
GO:0003700DNA-binding transcription factor activity-TAS8246996  
GO:0005515protein binding-IPI10779361  17380128  17438371  17517653  19249677  22157815  
25241761  
GO:0043565sequence-specific DNA binding-IDA23332764  
GO:0046983protein dimerization activity-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0006367transcription initiation from RNA polymerase II promoter-TAS8246996  
GO:0007049cell cycle-IEA-  
GO:0008284positive regulation of cell proliferation-IEA-  
GO:0045944positive regulation of transcription by RNA polymerase II-IDA7739537  
GO:0070345negative regulation of fat cell proliferation-ISS-  
GO:1905461positive regulation of vascular associated smooth muscle cell apoptotic process-IMP22886504  
GO ID GO Term Qualifier Evidence PubMed
GO:0005654nucleoplasm-TAS-  
GO:0090575RNA polymerase II transcription factor complex-IDA7739537  
KEGG ID KEGG Term
hsa04110Cell cycle
hsa05200Pathways in cancer
hsa05212Pancreatic cancer
hsa05214Glioma
hsa05215Prostate cancer
hsa05218Melanoma
hsa05219Bladder cancer
hsa05220Chronic myeloid leukemia
hsa05222Small cell lung cancer
hsa05223Non-small cell lung cancer
Reactome ID Reactome Term Evidence
R-HSA-157118Signaling by NOTCHIEA
R-HSA-157118Signaling by NOTCHTAS
R-HSA-162582Signal TransductionIEA
R-HSA-162582Signal TransductionTAS
R-HSA-1640170Cell CycleTAS
R-HSA-1912408Pre-NOTCH Transcription and TranslationIEA
R-HSA-1912408Pre-NOTCH Transcription and TranslationTAS
R-HSA-1912422Pre-NOTCH Expression and ProcessingIEA
R-HSA-1912422Pre-NOTCH Expression and ProcessingTAS
R-HSA-2262752Cellular responses to stressTAS
R-HSA-2559580Oxidative Stress Induced SenescenceTAS
R-HSA-2559583Cellular SenescenceTAS
R-HSA-2559585Oncogene Induced SenescenceTAS
R-HSA-453274Mitotic G2-G2/M phasesTAS
R-HSA-453279Mitotic G1-G1/S phasesTAS
R-HSA-68689CDC6 association with the ORC:origin complexTAS
R-HSA-68867Assembly of the pre-replicative complexTAS
R-HSA-68874M/G1 TransitionTAS
R-HSA-68911G2 PhaseTAS
R-HSA-69002DNA Replication Pre-InitiationTAS
R-HSA-69231Cyclin D associated events in G1TAS
R-HSA-69236G1 PhaseTAS
R-HSA-69278Cell Cycle, MitoticTAS
R-HSA-69306DNA ReplicationTAS
R-HSA-8953897Cellular responses to external stimuliTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
19390995Small cell lung cancer: significance of RB alterations and TTF-1 expression in its carcinogenesis, phenotype, and biology. (2009 Summer)Kitamura HEndocr Pathol